Annexon reports inducement grants to new employees under nasdaq listing rule 5635(c)(4)

Brisbane, calif., sept. 16, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 employment inducement award plan. the equity awards were approved on september 15, 2022, in accordance with nasdaq listing rule 5635(c)(4).
ANNX Ratings Summary
ANNX Quant Ranking